Novadaq Technologies Inc.

Novadaq Technologies Inc.

September 19, 2006 09:30 ET

Novadaq to Present at UBS Global Life Sciences Conference

Company to Provide Update on Clinical and Commercial Development for OPTTX and LUNA

TORONTO, ONTARIO--(Marketwire - Sept. 19, 2006) -

Attention Business Editors:

Novadaq® Technologies Inc. (TSX:NDQ), a developer of medical imaging systems
for the operating room, today announced that Dr. Rick Mangat, Vice-President,
General Manager, Cardiac and Novadaq Corp., will present the corporate story,
technology and highlights, including an update on clinical and commercial
development for both the OPTTX® and LUNA™ Systems, at the UBS Global Life
Sciences Conference. The conference runs from Monday, September 25 through
Thursday September 28 at the Grand Hyatt New York. Dr. Mangat presents at
4:00 p.m. on Monday, September 25.

About Novadaq Technologies

Novadaq Technologies Inc. (TSX:NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY® Intra-operative Imaging System, commercially available worldwide,
enables cardiac surgeons to visually assess coronary vasculature and bypass
graft functionality during the course of open-heart surgery. Novadaq's
ophthalmic product, the OPTTX System, is aimed at the diagnosis, evaluation
and treatment of wet Age-related Macular Degeneration (AMD) by using the same
core imaging technology that is used in the SPY System. Novadaq filed for CE
Mark approval for the OPTTX System at the end of Q2 2006 and expects a limited
launch in Europe by year end. Novadaq's product for urology, LUNA is designed
to enable surgeons to visualize nerve bundles during the course of urological
procedures such as radical prostatectomy in order to reduce negative outcomes
including impotency. For more information, please visit the company's website

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information: visit our website at

Contact Information